NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

多囊卵巢症候群 (PCOS)的全球市場(2021-2027)

Polycystic Ovary Syndrome (PCOS) Market 2021-2027

出版商 Orion Market Research Pvt Ltd 商品編碼 1025371
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
多囊卵巢症候群 (PCOS)的全球市場(2021-2027) Polycystic Ovary Syndrome (PCOS) Market 2021-2027
出版日期: 2021年06月30日內容資訊: 英文
簡介

在預測期內,多囊卵巢症候群 (PCOS)的市場規模預計將以約 4.0% 的顯著複合年增長率增長。女性多囊卵巢症候群患病率的上升是市場增長的主要驅動力。提高患者對 PCOS 治療可用性的認識也推動了 PCOS 治療市場的增長。 PCOS 的主要症狀包括體重快速增加、荷爾蒙變化、月經不調和不孕症。 PCOS 沒有特定的治療方法,但有許多藥物和治療方法可以治療這些症狀。因此,賽諾菲、諾華和梯瓦製藥工業有限公司等市場領導者都專注於開發 PCOS 的新藥和治療方法。此外,對 PCOS 治療的監管批准增加和伴隨藥物的增加也阻礙了市場增長。同時,對研發活動的高投資、政府加大力度提高對 PCOS 的認識以及技術進步可能會在預測期內進一步推動市場。

全球 PCOS 市場根據藥物類型、診斷、治療和分銷渠道進行分類。按藥物類型分為利尿劑、胰島素增敏劑、抗雄激素藥、抗抑鬱藥、鳥氨酸脫羧□抑製劑、抗肥胖藥和口服避孕藥。根據診斷,市場分為超聲檢查、盆腔檢查和血液檢查。另一方面,按治療方式分為卵巢楔形切除術、腹腔鏡卵巢切除術和針灸治療。隨著 PCOS 患病率的增加,預計腹腔鏡卵巢挖掘將主導市場。全球 PCOS 市場按分銷渠道分為醫院藥房、零售藥房(在線和離線)和生育診所。

按地域劃分,分為北美、歐洲、亞太等地區。在預測期內,北美和歐洲預計將主導市場。肥胖是該地區 PCOS 的主要原因之一,因此對 PCOS 治療和治療的需求很高,是市場增長的推動力。政府在醫療領域的報銷政策和人們對多囊卵巢症候群早期診斷的認識也支持了該地區的市場前景。此外,預計亞太地區在預測期內全球多囊卵巢症候群市場增長最快。大量患者的存在、政府對 PCOS 患病率增加的認識計劃以及 PCOS 具有成本效益的治療方法的進步是推動亞太地區 PCOS 市場增長的關鍵因素。市場領先的公司有雅培實驗室、阿斯利康公司、拜耳公司、百時美施貴寶、輝凌製藥、默克公司、諾華公司、梯瓦製藥工業有限公司等。

本報告調查了全球多囊卵巢症候群 (PCOS)市場、市場概況、市場增長和抑制因素分析、市場機會、藥物類型/診斷/治療/分銷渠道/地區。它提供了市場等系統信息規模趨勢和預測、競爭條件以及主要公司的概況。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
  • 重要的戰略分析
  • COVID-19 對主要參與者的影響

第 4 章市場決定因素

  • 增長因素
  • 抑制因素
  • 市場機會

第 5 章市場細分

  • 按藥物類型
    • 利尿劑
    • 胰島素增敏劑
    • 抗雄激素
    • 抗抑鬱藥
    • 鳥氨酸脫羧□抑製劑
    • 抗肥胖
    • 口服避孕藥
  • 按診斷類型
    • 超聲波
    • 內部檢查
    • 驗血
  • 按治療類型
    • 卵巢楔形切除術
    • 腹腔鏡卵巢穿孔
    • 針灸
  • 按分銷渠道
    • 醫院藥房
    • 零售藥店(線上和線下)
    • 不孕不育診所

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域
    • 拉丁美洲
    • 中東和非洲

第 7 章公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • AVA Science Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Dexa Medica(Dexa Group)
  • Ferring B.V.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Millendo Therapeutics, Inc.
  • MyOva
  • Novartis AG
  • PCOS Diva LLC
  • Pharmasure Ltd.
  • Sanofi SA
  • Sneha Natura
  • Teva Pharmaceutical Industries Ltd.
  • The Himalaya Drug Co.
  • Theralogix, LLC
目錄
Product Code: OMR2023787

Global Polycystic Ovary Syndrome (PCOS) Market Size, Share & Trends Analysis Report By Drug Type (Diuretics, Insulin Sensitizing Agents, Antiandrogens, Anti-Depressants, Ornithine Decarboxylase Inhibitors, and Others), By Diagnosis (Ultrasound, Pelvic Exam, and Others) By Treatment (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies (Online And Offline), And Fertility Clinics) Forecast, 2021-2027

The global market for PCOS is projected to have a considerable CAGR of around 4.0% during the forecast period. The rising prevalence of PCOS in women is the major factor driving the growth of the market. Additionally, growing awareness among the patient population about the availability of the treatment is fueling the growth of the PCOS treatment market. The sudden gain in weight, hormonal changes, irregular periods, and infertility are some of the major symptoms associated with PCOS. There is no specific treatment for PCOS,  however, there are numerous drugs and therapeutics used to treat these symptoms. Therefore, market leaders such as Sanofi, Novartis, Teva Pharmaceutical Industries Limited are focusing on developing novel drugs and treatments for PCOS. Moreover, the growing adoption of combination drugs and growing regulatory approvals to the drugs for PCOS is also exculpating the market growth. Whereas, the high investment for the R&D activities, and growing government initiatives to spread awareness about PCOS, and technological advancements are further projected to drive the market during the forecast period.

The Global PCOS market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on drug type, the market is segmented into diuretics, insulin-sensitizing agents, antiandrogens, anti-depressants, ornithine decarboxylase inhibitors, anti-obesity, and oral contraceptive pills. the insulin-sensitizing agents hold a major share owing to the wide adoption of the drug for the treatment of insulin resistance, to prevent diabetes which is one of the major causes of PCOS. Based on the diagnosis, the market is further classified into ultrasound, pelvic exam, and blood test. Whereas, the treatment segment is categorized into ovarian wedge resection, laparoscopic ovarian drilling, and acupuncture. Laparoscopic ovarian drilling is expected to dominate the market owing to the rising prevalence of PCOS. Similarly, based on distribution channels, the global PCOS market is segmented into hospital pharmacies, retail pharmacies (online and offline), and fertility clinics.

Geographically the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America and Europe are expected to dominate the market during the forecast period.  The presence of obese women population in this region is creating a high demand for PCOS drugs and treatments, as obesity is one of the major causes of PCOS, which in turn, driving the market growth. reimbursement policies by the government in the healthcare sector and awareness amongst the population regarding the early diagnosis of PCOS are also boosting the market prospects in the regions. Furthermore, the Asia-Pacific is projected to exhibit the fastest growth in the global polycystic ovary syndrome market over the forecast period. The presence of a large patient pool, government awareness programs regarding the growing prevalence of PCOS, and advancement in cost-effective treatments for PCOS are the major factors driving the growth of the PCOS market in the Asia-pacific region. The key players of the market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals, Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., among others.

Research Methodology

The market study of the global polycystic ovary syndrome (PCOS) market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by Product Type
  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by Material
  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by End-user

The Report Covers

  • Comprehensive research methodology of the global polycystic ovary syndrome (PCOS) market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global polycystic ovary syndrome (PCOS) market.
  • Insights about market determinants that are stimulating the global polycystic ovary syndrome (PCOS) market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the GlobalPCOS Industry
  • Recovery Scenario of Global PCOS Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global PCOS Market, ByDrug Type
    • 5.1.1. Diuretics
    • 5.1.2. Insulin Sensitizing Agents
    • 5.1.3. Antiandrogens
    • 5.1.4. Anti-Depressants
    • 5.1.5. Ornithine Decarboxylase Inhibitors
    • 5.1.6. Anti-Obesity
    • 5.1.7. Oral Contraceptive Pills
  • 5.2. Global PCOSMarket, By Diagnosis Type
    • 5.2.1. Ultrasound
    • 5.2.2. Pelvic Exam
    • 5.2.3. Blood Test
  • 5.3. Global PCOSMarket, By Treatment Type
    • 5.3.1. Ovarian Wedge Resection
    • 5.3.2. Laparoscopic Ovarian Drilling
    • 5.3.3. Acupuncture
  • 5.4. Global PCOSMarket, By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies (Online and Offline)
    • 5.4.3. Fertility Clinics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Russia
    • 6.2.7. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korean
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East& Africa

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Astellas Pharma Inc.
  • 7.3. AstraZeneca plc
  • 7.4. AVA Science Inc.
  • 7.5. Bayer AG
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Dexa Medica (Dexa Group)
  • 7.8. Ferring B.V.
  • 7.9. GlaxoSmithKline plc
  • 7.10. Merck & Co., Inc.
  • 7.11. Millendo Therapeutics, Inc.
  • 7.12. MyOva
  • 7.13. Novartis AG
  • 7.14. PCOS Diva LLC
  • 7.15. Pharmasure Ltd.
  • 7.16. Sanofi SA
  • 7.17. Sneha Natura
  • 7.18. Teva Pharmaceutical Industries Ltd.
  • 7.19. The Himalaya Drug Co.
  • 7.20. Theralogix, LLC

LIST OF TABLES

  • 1. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 2. GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL INSULIN SENSITIZING AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ANTIANDROGENS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL ANTI-DEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ANTI-OBESITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 10. GLOBAL ULTRASOUND FOR PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL PELVIC EXAM FOR PCOSMARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 12. GLOBAL BLOOD TEST FOR PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 14. GLOBAL OVARIAN WEDGE RESECTION IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL ACUPUNCTURE IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 18. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL FERTILITY CLINICS IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 26. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 28. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 29. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 30. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE,2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYTREATMENT TYPE, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE,2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYTREATMENT TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL PCOSMARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL PCOSMARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL PCOSMARKET, 2020-2027 (%)
  • 4. GLOBAL PCOSMARKET SHARE BYDRUG TYPE,2020 VS 2027 (%)
  • 5. GLOBAL PCOSMARKET SHARE BYDIAGNOSIS TYPE,2020 VS 2027 (%)
  • 6. GLOBAL PCOSMARKET SHARE BY TREATMENT TYPE,2020 VS 2027 (%)
  • 7. GLOBAL PCOSMARKET SHARE BY DISTRIBUTION CHANNEL,2020 VS 2027 (%)
  • 8. GLOBAL PCOSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL DIURETICS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL INSULIN SENSITIZING AGENTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL ANTIANDROGENS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL ANTI-DEPRESSANTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL ANTI-OBESITY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL ULTRASOUND FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL PELVIC EXAM FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL BLOOD TEST FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL OVARIAN WEDGE RESECTION IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL ACUPUNCTURE IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 23. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 24. GLOBAL FERTILITY CLINICS IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 25. UK PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 26. FRANCE PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 27. GERMANY PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 28. ITALY PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 29. SPAIN PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF EUROPE PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 31. INDIA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 32. CHINA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 33. JAPAN PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SOUTH KOREA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC PCOSMARKET SIZE, 2020-2027 ($ MILLION)

36. REST OF THE WORLD PCOSMARKET SIZE, 2021-2027($ MILLION